FDA Approves BUPRENORPHINE — Teva Pharmaceuticals USA, Inc.

Teva Pharmaceuticals USA, Inc. secured FDA approval for its ANDA for buprenorphine transdermal (brand name Bluprenorphine LT) on Tuesday, positioning the firm to compete in the pain management market. The generic approval allows lower- and medium-strength patches to enter the market, which may face pricing pressure from higher-strength competitors while diversifying Teva’s portfolio in the controlled substance sector.